{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:50:28Z","timestamp":1783813828089,"version":"3.55.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008129","name":"Helsinn","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009032","name":"Pfizer Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009032","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.leukres.2022.106984","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T12:02:28Z","timestamp":1667390548000},"page":"106984","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed\/refractory acute myeloid leukemia"],"prefix":"10.1016","volume":"123","author":[{"given":"Sameem M.","family":"Abedin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1548-918X","authenticated-orcid":false,"given":"Talha","family":"Badar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelyn","family":"Gauger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C.","family":"Michaelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Runaas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen-Sue","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GS Guru","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9919-3564","authenticated-orcid":false,"given":"Ehab","family":"Atallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.leukres.2022.106984_bib1","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1634\/theoncologist.2017-0604","article-title":"FDA approval summary: mylotarg for treatment of patients with relapsed or refractory CD33\u2013positive acute myeloid leukemia","volume":"23","author":"Norsworthy","year":"2018","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.leukres.2022.106984_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-017-0456-2","article-title":"Treatment of relapsed\/refractory acute myeloid leukemia","volume":"18","author":"Bose","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"issue":"2","key":"10.1016\/j.leukres.2022.106984_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.leu.2404477","article-title":"The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells","volume":"21","author":"ten Cate","year":"2007","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2022.106984_bib4","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3324\/haematol.2013.096545","article-title":"Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I\/II study","volume":"99","author":"Walter","year":"2014","journal-title":"Haematologica"},{"issue":"24","key":"10.1016\/j.leukres.2022.106984_bib5","doi-asserted-by":"crossref","first-page":"4851","DOI":"10.1002\/cncr.30949","article-title":"Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies","volume":"123","author":"Abaza","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.leukres.2022.106984_bib6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/bloodadvances.2018027409","article-title":"Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study","volume":"3","author":"Garcia-Manero","year":"2019","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.leukres.2022.106984_bib7","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3324\/haematol.2020.252569","article-title":"Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens","volume":"106","author":"Abhishek","year":"2020","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"10.1016\/j.leukres.2022.106984_bib8","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1182\/blood-2021-145184","article-title":"Retrospective analysis of the outcomes of patients with relapsed\/refractory acute myeloid leukemia included in a patient named program of gemtuzumab ozogamicin","volume":"138","author":"Lambert","year":"2021","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622003605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212622003605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:49Z","timestamp":1758935029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212622003605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":8,"alternative-id":["S0145212622003605"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106984","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of pracinostat in combination with gemtuzumab ozogamicin (PraGO) in patients with relapsed\/refractory acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2022.106984","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106984"}}